AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 83 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,233,265 | -53.2% | 2,688,873 | -44.8% | 1.64% | -46.0% |
Q2 2023 | $105,130,433 | -40.6% | 4,873,919 | -19.2% | 3.04% | -41.8% |
Q1 2023 | $177,056,455 | -21.3% | 6,034,644 | -0.9% | 5.23% | -17.2% |
Q4 2022 | $224,963,904 | +46.0% | 6,088,333 | +11.3% | 6.32% | +41.3% |
Q3 2022 | $154,038,000 | +125.9% | 5,472,033 | +54.6% | 4.47% | +109.3% |
Q2 2022 | $68,188,000 | +260.0% | 3,540,408 | +140.2% | 2.14% | +463.6% |
Q1 2022 | $18,942,000 | – | 1,474,107 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |